2024 Arcus biosciences stock - Arcus Biosciences, Inc. (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Find the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing.

 
In a report released on September 14, Robyn Karnauskas from Truist Financial maintained a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $50.00.The company’s .... Arcus biosciences stock

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and provided a pipeline update on its six clinical-stage investigational molecules ...Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting ...Arcus Biosciences, Inc. (RCUS) closed the last trading session at $28.63, gaining 12.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...An in-depth examination of risks revealed 2 warning signs for Arcus Biosciences that readers should think about before committing capital to this stock. Of course, you might find a fantastic ...Nov 7, 2023 · Analyst Mara Goldstein of Mizuho Securities maintained a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $51.00. Mara Goldstein’s Buy recommendation for Arcus ... Investigating Combination Therapies to Treat Cancer. Learn how cancer biology is guiding the study of potential, new combination medicines to treat specific types of cancer. Read More. Arcus is a biopharmaceutical company aiming to bring together scientists, physicians & advisors to focus on developing best-in-class cancer therapies. Complete Arcus Biosciences Inc. stock information by Barron's. View real-time RCUS stock price and news, along with industry-best analysis.Nov 27, 2023 · Sell candidate since Nov 09, 2023 Gain 2.33% PDF. No changes to the price of Arcus Biosciences Inc. stock on the last trading day (Monday, 27th Nov 2023). During the last trading day the stock fluctuated 4.63% from a day low at $13.50 to a day high of $14.12. The price has risen in 5 of the last 10 days and is up by 3.84% over the past 2 weeks. During the last session, Arcus Biosciences Inc (NYSE:RCUS)’s traded shares were 0.79 million, with the beta value of the company hitting 0.69. At the end of the trading day, the stock’s price was $16.07, reflecting an intraday gain of 6.71% or $1.01. The 52-week high for the RCUS share is $36.13 ...Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced it will report financial results and key pipeline updates for the first quarter ended March 31, 2022 after the U.S. …Dr. Jaen owns 218,258 shares of Arcus Biosciences stock worth more than $3,127,637 as of October 29th. This net worth approximation does not reflect any other assets that Dr. Jaen may own. Additionally, Dr. Jaen receives a salary of $931,140.00 as President at Arcus Biosciences. Learn More about Juan C. Jaen's net worth.Calendar Arcus Biosciences, Inc. Equities. RCUS. US03969F1093. Market Closed - Nyse. Other stock markets.With a median price-to-sales (or "P/S") ratio of close to 11.6x in the Biotechs industry in the United States, you could be forgiven for feeling indifferent about Arcus Biosciences, Inc.'s () P/S ...HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced seven accepted abstracts at the 2023 American Society of Clinical Oncology (ASCO) …Teleprensa World La Policía Nacional desarticula en Jaén un grupo criminal dedicado ... Teleprensa World JAÉN.- Agentes de la Policía Nacional desarticularon en Jaén, un grupo criminal muy activo dedicado a la distribución y venta de cocaína. La información fue recibida a través de la dirección de correo electrónico …Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to earnings of $3.71 per share a year ago.Domvanalimab, Arcus Biosciences’ Phase 3 cancer immunotherapy drug, shows promise in treating lung and gastrointestinal cancers, but faces a competitive anti-TIGIT market. ... In stock momentum ...HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a pipeline …While ratings are subjective and will change, the latest Arcus Biosciences ( RCUS) rating was a maintained with a price target of $46.00 to $36.00. The current price Arcus Biosciences ( RCUS) is ...Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently up 3.95% so far this month. During the month of April, Arcus Biosciences Inc’s stock price has reached a high of $19.03 and a low of $16.94. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $15.70. Year to date ...Arcus Biosciences Inc stocks price quote with latest real-time prices, charts, financials, latest news, ... Unique to Barchart.com, Opinions analyzes a stock or commodity using …Track Arcus Biosciences Inc (RCUS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsArcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is …Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting ...Nov 23, 2023 · Arcus Biosciences Stock Performance. NYSE RCUS opened at $13.87 on Thursday. Arcus Biosciences has a one year low of $12.95 and a one year high of $36.13. The firm’s fifty day moving average is $16.47 and its two-hundred day moving average is $18.74. The firm has a market cap of $1.04 billion, a PE ratio of -3.47 and a beta of 0.76. Nov 27, 2023 · Sell candidate since Nov 09, 2023 Gain 2.33% PDF. No changes to the price of Arcus Biosciences Inc. stock on the last trading day (Monday, 27th Nov 2023). During the last trading day the stock fluctuated 4.63% from a day low at $13.50 to a day high of $14.12. The price has risen in 5 of the last 10 days and is up by 3.84% over the past 2 weeks. Reported on 11/7/23. Get the latest Arcus Biosciences Inc (RCUS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and ... 28 чэр 2023 г. ... ARCUS BIOSCIENCES, INC. (Name of Issuer). Common Stock, par value $0.0001. (Title of Class of Securities). 03969F109. (CUSIP Number). Gilead ...HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a pipeline …– Gilead to Have Early Option to Exclusively License Drug Candidates Against up to Four Targets for Inflammatory Diseases – – Expanded Research Collaboration May Result in up to $1 Billion in Option Fees and Milestone Payments by Gilead to Arcus – Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) …Arcus Biosciences beat estimated earnings by 17.54%, reporting an EPS of $-0.94 versus an estimate of $-1.14. Revenue was down $1.58 million from the same period last year. Past Earnings PerformanceArcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently down 6.96% so far this month. During the month of April, Arcus Biosciences Inc’s stock price has reached a high of $18.51 and a low of $16.94. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $15.70. Year to …Jarrett Jennifer, the Chief Operating Officer of Arcus Biosciences Inc, sale 45,000 shares at $20.25 during a trade that took place back on Jul 28, which means that Jarrett Jennifer is holding 336,566 shares at $911,250 based on the most recent closing price. Stock Fundamentals for RCUS. Current profitability levels for the company are sitting at:Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Mar 2, 2023 · In a report released on March 1, Daina Graybosch from SVB Securities maintained a Buy rating on Arcus Biosciences ( RCUS – Research Report ). The company’s shares closed yesterday at $17.57 ... Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently down 0.89% so far this month. During the month of November, Arcus Biosciences Inc’s stock price has reached a high of $16.76 and a low of $15.35. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $14.33. Year to date ...Nov 29, 2023 · Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop ... During the last session, Arcus Biosciences Inc (NYSE:RCUS)’s traded shares were 0.88 million, with the beta value of the company hitting 0.75. At the end of the trading day, the stock’s price was $16.01, reflecting an intraday loss of -2.67% or -$0.44. The 52-week high for the RCUS share is $36.Stock analysis for Arcus Biosciences Inc (RCUS:New York) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Jun 15, 2023 · I last covered Arcus Biosciences (NYSE:RCUS) for Seeking Alpha back in March 2020, giving the company' stock a "BUY" rating - more than 3 years later, Arcus stock has reached a value of $20 at the ... Arcus Biosciences (RCUS Quick Quote RCUS - Free Report) has an Earnings ESP of +29.01% and a Zacks Rank #1. Arcus Biosciences’ stock has declined 24.9% in the past year.SVP, Technology & Quantitative Biology. Dr. Young has held scientific, technical, and leadership roles across Europe and the U.S. since 1993, most recently as VP of Technology at Flexus Biosciences and FLX Bio. He was the first scientist at Flexus and built the company’s biology and IT/informatics functions from the ground up …. Arcus Biosciences (RCUS Quick Quote RCUS - Free Report) has an Earnings ESP of +29.01% and a Zacks Rank #1. Arcus Biosciences’ stock has declined 24.9% in the past year.Nov 27, 2023 · Arcus Biosciences, Inc. (NYSE:RCUS) released its earnings results on Tuesday, November, 7th. The company reported ($0.94) earnings per share for the quarter, beating analysts' consensus estimates of ($1.12) by $0.18. The firm had revenue of $32 million for the quarter, compared to analyst estimates of $27.57 million. Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 12,600 shares of the Company’s common stock at an exercise price ...In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies.The parties will co-develop Gilead-optioned programs globally and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs. Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently up 0.16% so far this month. During the month of March, Arcus Biosciences Inc’s stock price has reached a high of $18.88 and a low of $15.70. Over the last year, Arcus Biosciences Inc has hit prices as high as $39.75 and as low as $15.70. Year to date ...Arcus Biosciences stock is on fire in response to a possible partnership deal with Gilead Sciences. What happened Arcus Biosciences, Inc. ( RCUS -5.44% ) , a clinical-stage oncology company, is up ...Arcus Biosciences beat estimated earnings by 17.54%, reporting an EPS of $-0.94 versus an estimate of $-1.14. Revenue was down $1.58 million from the same period last year. Past Earnings Performance– 35-45% Reduction in Risk of Progression or Death and a Doubling of mPFS Were Observed in the Domvanalimab-Containing Study Arms, Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC – – With Median Follow-Up of Approximately 12 Months, Both Domvanalimab-Containing Study Arms Also Improved …Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. Arcus is evaluating zimberelimab in combination with multiple molecules within the Arcus portfolio, including several registrational Phase 3 ...Zimberelimab (誉妥®) is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma. Based on the results of a …On average, Wall Street analysts predict that Arcus Biosciences's share price could reach $44.38 by Nov 13, 2024. The average Arcus Biosciences stock price ...Oct 31, 2023 · Arcus Biosciences, Inc. Appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ... Get the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing. See the current price, performance outlook, earnings date, dividend yield, fair value and more.Find the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing.In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Arcus Biosciences (RCUS - Research Report), with a pr...HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and provided a pipeline update on its six clinical-stage investigational molecules ...HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and provided a pipeline update on its six clinical-stage investigational molecules ...HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a pipeline …Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting ...Complete Arcus Biosciences Inc. stock information by Barron's. View real-time RCUS stock price and news, along with industry-best analysis. May 15, 2023 · This transaction with Arcus is expected to reduce Gilead’s GAAP and non-GAAP 2023 EPS by $0.02. About Arcus Biosciences. Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. Arcus Biosciences, Inc. Common Stock (RCUS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Arcus’s growing employee base and 2021 stock awards drove an increase in employee compensation costs, including approximately $2.7 million of increased non-cash stock-based compensation. General and administrative expenses were $72.3 million for the full year ended December 31, 2021, compared to $42.4 million for the same period in 2020.Apr 12, 2023 · Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently down 6.96% so far this month. During the month of April, Arcus Biosciences Inc’s stock price has reached a high of $18.51 and a low of $16.94. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $15.70. Year to date ... HAYWARD, Calif., December 24, 2022 -- ( BUSINESS WIRE )--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today ...According to the issued ratings of 8 analysts in the last year, the consensus rating for Arcus Biosciences stock is Moderate Buy based on the current 1 hold rating and 7 buy ratings for RCUS. The average twelve-month price prediction for Arcus Biosciences is $43.13 with a high price target of $70.00 and a low price target of $23.00.HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced several poster presentations at upcoming scientific conferences that support the ongoing …Nov 7, 2023 · Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently up 4.71% so far this month. During the month of November, Arcus Biosciences Inc’s stock price has reached a high of $16.76 and a low of $15.35. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $14.33. Year to date ... HAYWARD, Calif., December 24, 2022 -- ( BUSINESS WIRE )--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today ...HAYWARD, Calif.--(BUSINESS WIRE)--Nov. 27, 2023-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company …Arcus Biosciences' (NYSE:RCUS) stock is up by a considerable 39% over the past three months. We wonder if and what role the company's financials play in that price change as a company's long-term ...Camaraderie, teamwork, integrity. The complexity and cross-functional nature of what we do makes strong teamwork essential to our success. We take pride in hard work and approach our mission with a great sense of urgency. We embrace innovative mindsets and the change this brings. And finally, we aspire to operate with simplicity and common ... Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to earnings of $3.71 per share a year ago.Dr. Jaen owns 218,258 shares of Arcus Biosciences stock worth more than $3,127,637 as of October 29th. This net worth approximation does not reflect any other assets that Dr. Jaen may own. Additionally, Dr. Jaen receives a salary of $931,140.00 as President at Arcus Biosciences. Learn More about Juan C. Jaen's net worth.An in-depth examination of risks revealed 2 warning signs for Arcus Biosciences that readers should think about before committing capital to this stock. Of course, you might find a fantastic ...Calendar Arcus Biosciences, Inc. Equities. RCUS. US03969F1093. Market Closed - Nyse. Other stock markets.Check if RCUS Stock has a Buy or Sell Evaluation. RCUS Stock Price (NYSE), Forecast, Predictions, Stock Analysis and Arcus Biosciences Inc. News.Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing …FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today that the companies have entered into a 10-year …This transaction with Arcus is expected to reduce Gilead’s GAAP and non-GAAP 2023 EPS by $0.02. About Arcus Biosciences. Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer.Employment- Arcus Biosciences . Stock and Other Ownership Interests - Arcus Biosciences . Thao Dang, MD. Employment- Gilead Sciences . Stock and Other Ownership Interests- Gilead Sciences . Travel, Accommodations, Expenses - Gilead Sciences . Patrick Hoang Phuong, PharmD .Nov 22, 2023 · Arcus Biosciences stock has received a consensus rating of buy. The average rating score is and is based on 19 buy ratings, 3 hold ratings, and 0 sell ratings. What was the 52-week low for Arcus ... Arcus Biosciences’ stock has declined 32.7% in the past year. Earnings of RCUS beat estimates in two of the last four quarters, missed the mark on one occasion and met the mark on another.Evasões 7 vinhos de casta jaen do Dão que vale a pena experimentar Evasões Lugar referencial de todo o Dão moderno, este jaen tem tudo o que é preciso para perceber a casta. Atenção, está praticamente esgotado. Classificação Evasões: 17,5. Preço: 10 euros. Quinta-das-Maias-Jaen. Quinta das Maias Jaen DOC Dão tinto 2013 ...Shares of Arcus Biosciences (RCUS 3.13%), a clinical-stage biopharmaceutical company, are on the move following a progress report for the company's most valuable asset at the moment.In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies.The parties will co-develop Gilead-optioned programs globally and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.Jun 15, 2023 · I last covered Arcus Biosciences (NYSE:RCUS) for Seeking Alpha back in March 2020, giving the company' stock a "BUY" rating - more than 3 years later, Arcus stock has reached a value of $20 at the ... Phase 1/1b results for the etrumadenant combination demonstrated a 4.2 month PFS, approximately double the 2 months reported for current standard of care therapies in the ≥3L mCRC setting ARC-9, a randomized Phase 1b/2 platform study, has been initiated to further evaluate etrumadenant-zimberelimab combinations in the 2L, 3L …Arcus biosciences stock

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT .... Arcus biosciences stock

arcus biosciences stock

The current Arcus Biosciences [ RCUS] share price is $14.06. The Score for RCUS is 46, which is 8% below its historic median score of 50, and infers higher risk than normal. RCUS is currently trading in the 40-50% percentile range relative to …The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting …Nov 7, 2023 · Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently up 4.71% so far this month. During the month of November, Arcus Biosciences Inc’s stock price has reached a high of $16.76 and a low of $15.35. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $14.33. Year to date ... In the last 3 months, 9 analysts have offered 12-month price targets for Arcus Biosciences. The company has an average price target of $46.33 with a high of $70.00 and a low of $23.00. Below is a ...Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. The company has major deals with Gilead, Roche/Genentech, and AstraZeneca, and ...Find out the latest news, events, and updates on Arcus Biosciences, a biotechnology company that develops cancer immunotherapies. See the stock quote, SEC filings, press releases, and investor relations information on their website.Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced seven accepted abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be …... Inc. Announces Pricing of $302.5 Million Underwritten Public Offering of Common Stock. May 28, 2020 10:37 PM Eastern Daylight Time. HAYWARD, Calif.Get prepared with the key expectations. Find the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading …Real time Arcus Biosciences (RCUS) stock price quote, stock graph, news & analysis. On average, Wall Street analysts predict that Arcus Biosciences's share price could reach $44.38 by Nov 13, 2024. The average Arcus Biosciences stock price ...HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT ...Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic …Get the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing. See the current price, performance outlook, earnings date, dividend yield, fair value and more.Oct 31, 2023 · Arcus Biosciences, Inc. Appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ... US03969F1093. Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and …HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a pipeline …Dec 1, 2023Employment- Arcus Biosciences . Stock and Other Ownership Interests - Arcus Biosciences . Thao Dang, MD. Employment- Gilead Sciences . Stock and Other Ownership Interests- Gilead Sciences . Travel, Accommodations, Expenses - Gilead Sciences . Patrick Hoang Phuong, PharmD .Employment- Arcus Biosciences . Stock and Other Ownership Interests - Arcus Biosciences . Thao Dang, MD. Employment- Gilead Sciences . Stock and Other Ownership Interests- Gilead Sciences . Travel, Accommodations, Expenses - Gilead Sciences . Patrick Hoang Phuong, PharmD .Concurrent with the May 2020 collaboration agreement, Gilead and Arcus entered into a stock purchase agreement under which Gilead made a $200 million equity investment in Arcus. That stock ...Arcus Biosciences Stock Performance. NYSE RCUS opened at $13.87 on Thursday. Arcus Biosciences has a one year low of $12.95 and a one year high of $36.13. The firm’s fifty day moving average is $16.47 and its two-hundred day moving average is $18.74. The firm has a market cap of $1.04 billion, a PE ratio of -3.47 and a beta of 0.76.Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 31,200 shares of the Company’s common stock at an exercise price ...What happened. Shares of Arcus Biosciences (RCUS 6.71%) jumped by as much as 21% in premarket trading Thursday morning. The biotech's stock is heating up in early morning action today on the news ...Find real-time RCUS - Arcus Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business. In a report released on September 14, Robyn Karnauskas from Truist Financial maintained a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $50.00.The company’s ...Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. Arcus is evaluating zimberelimab in combination with multiple molecules within the Arcus portfolio, including several registrational Phase 3 ...Arcus Biosciences is a clinical-stage biopharmaceutical company that develops and commercializes cancer therapies. The stock price, news, and analysis of …Jan 10, 2022 · HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today provided updates on clinical programs and key milestones anticipated in 2022. According to 10 stock analysts, the average 12-month stock price forecast for RCUS stock stock is $42.6, which predicts an increase of 202.99%. The lowest target is $23 and the highest is $70. On average, analysts rate RCUS stock stock as a strong buy.Jan 10, 2022 · HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today provided updates on clinical programs and key milestones anticipated in 2022. 13 вер 2023 г. ... Arcus Biosciences Inc (RCUS) stock is trading at $21.32 as of 11:53 AM on Wednesday, Sep 13, a gain of $0.09, or 0.42% from the previous closing ...In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies.The parties will co-develop Gilead-optioned programs globally and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.Which technical analysis tools can be used to analyze Arcus Biosciences, Inc.? Check out various oscillators, moving averages and other technical indicators ...Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently down 6.96% so far this month. During the month of April, Arcus Biosciences Inc’s stock price has reached a high of $18.51 and a low of $16.94. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $15.70. Year to date ...Find real-time RCUS - Arcus Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business. Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.Since March 15, 2018, Arcus Biosciences's market cap has increased from $708.10M to $1.04B, an increase of 46.52%. That is a compound annual growth rate of 6.93 ...Arcus Biosciences, Inc. Common Stock (RCUS) Stock Price, Quote, News & History | Nasdaq Created with Sketch. Market Activity Funds + ETFs News + Insights P/E & PEG Ratios when trading,...Shares of Arcus Biosciences ( RCUS 6.71%) jumped by as much as 21% in premarket trading Thursday morning. The biotech's stock is heating up in early morning action today on the news that Gilead ...Nov 29, 2023 · Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop ... – Gilead to Have Early Option to Exclusively License Drug Candidates Against up to Four Targets for Inflammatory Diseases – – Expanded Research Collaboration May Result in up to $1 Billion in Option Fees and Milestone Payments by Gilead to Arcus – Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) …15 мая 2023 г. ... Gilead is paying $35 million cash to expand an existing oncology partnership with Arcus Biosciences into inflammatory diseases.AstraZeneca and Arcus have a clinical collaboration on Pacific-8 a Phase III study evaluating our anti-TIGIT antibody domvanalimab plus durvalumab (Imfinzi®) for stage 3 non-small cell lung cancer with curative intent. Welcome to investor relations at Arcus Biosciences. We're at the forefront of designing highly-combinable, best-in-class ... Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting ... Dec 1, 2023 · See the latest Arcus Biosciences Inc stock price (RCUS:XNYS), related news, valuation, dividends and more to help you make your investing decisions. In a report released on September 14, Robyn Karnauskas from Truist Financial maintained a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $50.00.The company’s ...HAYWARD, Calif., December 24, 2022--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...Arcus Biosciences (RCUS) stock price prediction is 40.382134862897 USD. The Arcus Biosciences stock forecast is 40.382134862897 USD for 2024 November 27, ...Arcus Biosciences Inc recently saw a daily gain of 27.7% and a 3-month gain of 29.03%.However, with a Loss Per Share of 3.96, is the stock truly undervalued? This article provides a comprehensive ...Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update. August 7, 2023. ... In June 2023, Arcus sold 1.0 million shares of common stock to Gilead at a purchase price of $19.26 per share, increasing Gilead’s ownership to 19.9%. Gross proceeds to Arcus from the transaction were $19.5 million.Exelixis, Inc. (EXEL) and Arcus Biosciences (RCUS) have announced a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis' next-generation tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors, …5 сак 2018 г. ... March 5 (Reuters) -. * ARCUS BIOSCIENCES INC ‍​NOW SEES IPO OF UP TO 7.1 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $13.00 AND $15.00 PER ...In a report released on September 14, Robyn Karnauskas from Truist Financial maintained a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $50.00.The company’s .... Apple stock forcast